U.S. Markets close in 4 hrs 10 mins

Delcath Systems to Present at the 9th Annual LD Micro Main Event

LOS ANGELES, CA / ACCESSWIRE / November 30, 2016 / Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Company management will be presenting at the 9th annual LD Micro Main Event on Wednesday, December 7th at 12:00 PM PST (3:00 PM EST) at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath, will be presenting a corporate overview, as well as meeting with investors.

The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenting names.

Dr. Simpson's presentation will be webcast live and archived for 90 days on the Company's website at www.delcath.com.

View Delcath Systems' profile here: http://www.ldmicro.com/profile/DCTH

News Compliments of Accesswire.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and a global Phase 2 clinical trial in Europe and the U.S. to investigate the Melphalan/HDS system for the treatment of primary liver cancer (HCC) and intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events for more information.

Investor Contact:

Anne Marie Fields
LHA
212-838-3777
afields@lhai.com

SOURCE: Delcath Systems, Inc. via LD Micro